

# Jing Luo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2964976/publications.pdf>

Version: 2024-02-01

25  
papers

558  
citations

933447

10  
h-index

642732

23  
g-index

25  
all docs

25  
docs citations

25  
times ranked

615  
citing authors

#	ARTICLE	IF	CITATIONS
1	Incidence and Predictors of Primary Nonadherence to Sodium Glucose Co-transporter 2 Inhibitors and Glucagon-Like Peptide 1 Agonists in a Large Integrated Healthcare System. <i>Journal of General Internal Medicine</i> , 2022, 37, 3562-3569.	2.6	7
2	Association of formulary restrictions and initiation of an SGLT2i or GLP1-RA among Medicare beneficiaries with type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2022, 187, 109855.	2.8	4
3	Potential Gains in Life Expectancy Associated With Achieving Treatment Goals in US Adults With Type 2 Diabetes. <i>JAMA Network Open</i> , 2022, 5, e227705.	5.9	15
4	Projected Impact of the Medicare Part D Senior Savings Model on Diabetes-Related Health and Economic Outcomes Among Insulin Users Covered by Medicare. <i>Diabetes Care</i> , 2022, 45, 1814-1821.	8.6	4
5	Access to Affordable Insulin and Epinephrine Autoinjectors Through Federally Qualified Health Centers. <i>JAMA Health Forum</i> , 2021, 2, e210313.	2.2	2
6	Estimates of insulin needs and dispensation given wastage, alternative glycemic targets, and non-insulin therapies in US populations with type 2 diabetes mellitus: A microsimulation study. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107839.	2.3	4
7	An Unnecessary Gift for COVID-19 Vaccines and Therapeutics: The Medical Countermeasure Priority Review Voucher. <i>American Journal of Public Health</i> , 2021, 111, e1-e4.	2.7	0
8	Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US. <i>JAMA Health Forum</i> , 2021, 2, e214182.	2.2	58
9	Coverage, Formulary Restrictions, and Out-of-Pocket Costs for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Medicare Part D Program. <i>JAMA Network Open</i> , 2020, 3, e2020969.	5.9	66
10	iNOS/NO is required for IRF1 activation in response to liver ischemia-reperfusion in mice. <i>Molecular Medicine</i> , 2020, 26, 56.	4.4	11
11	Origins of the Crisis in Insulin Affordability and Practical Advice for Clinicians on Using Human Insulin. <i>Current Diabetes Reports</i> , 2020, 20, 2.	4.2	11
12	Insulin access and affordability in the USA: anticipating the first interchangeable insulin product. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 360-362.	11.4	4
13	Challenges and Opportunities for Biomarker Validation. <i>Journal of Law, Medicine and Ethics</i> , 2019, 47, 357-361.	0.9	9
14	Implementation of a Health Plan Program for Switching From Analogue to Human Insulin and Glycemic Control Among Medicare Beneficiaries With Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 374.	7.4	31
15	Insulin for all: treatment activism and the global diabetes crisis. <i>Lancet</i> , 2019, 393, 2116-2117.	13.7	9
16	Academic Detailing in the New Era of Diabetes Medication Management. <i>Current Diabetes Reports</i> , 2019, 19, 140.	4.2	3
17	Cost-Related Insulin Underuse Among Patients With Diabetes. <i>JAMA Internal Medicine</i> , 2019, 179, 112.	5.1	156
18	Strategies to improve the affordability of insulin in the USA. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 158-159.	11.4	33

#	ARTICLE	IF	CITATIONS
19	Comparative effectiveness and safety of thalidomide and lenalidomide in patients with multiple myeloma in the United States of America: A population-based cohort study. <i>European Journal of Cancer</i> , 2017, 70, 22-33.	2.8	28
20	Effect of Generic Competition on Atorvastatin Prescribing and Patients' Out-of-Pocket Spending. <i>JAMA Internal Medicine</i> , 2016, 176, 1317.	5.1	32
21	Insulin patents and market exclusivities: unresolved issues – Authors' reply. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 98-99.	11.4	6
22	Trends in Medicaid Reimbursements for Insulin From 1991 Through 2014. <i>JAMA Internal Medicine</i> , 2015, 175, 1681.	5.1	41
23	Cost-effectiveness of Statin Therapy for ASCVD. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 2191.	7.4	0
24	Evolution of insulin patents and market exclusivities in the USA. <i>Lancet Diabetes and Endocrinology</i> , 2015, 3, 835-837.	11.4	23
25	Peripancreatic Enhancing Lesion in a Cirrhotic Patient. <i>Gastroenterology</i> , 2014, 146, 35-325.	1.3	1